




Radiation Therapy
Oncology Group

RTOG Report to ATC Steering Committee





Radiation Therapy
Oncology Group

RTOG Headquarters Provides:

- Medical Dosimetrist QA review of advanced technology clinical trials using the ATC web-based remote review tools (RRT).
- Dose-volume analysis of case data in RTOG protocols.
- RTOG HQ staff arranges for conference calls.
- A review of all advanced technology protocols that are developed through the ATC to help ensure uniformity of guidelines.
- Expertise in maintaining and improving in electronic links between RTOG's clinical trial database and the ITC's treatment planning and verification (TPV) database;



Radiation Therapy
Oncology Group

RTOG Headquarters Provides (cont.)

- Credentialing process monitoring through the ITC and RPC.
- Identify and implement common ID numbers for pts on RTOG protocols
- Collaboration with NSABP for the Phase III PBI breast cancer trial.
- Resource for continued learning/education of the credentialing processes for Advanced Technology protocols.



Radiation Therapy
Oncology Group

ATC Review Workstation at RTOG HQ's in Philadelphia, PA





Radiation Therapy
Oncology Group

IMAGE-GUIDED THERAPY CENTER [ITC]

Protocol RTOG-P0126 Dose-Volume Analysis QA Review for: Cross Cancer Institute

Patient Initials: P. W. Case #: 9 0126c0009

Group: 2 Dose Level: Rx Dose: 72.93 (See Appendix I)

A. TARGET VOLUME ANALYSIS

Target	Volume (cc)	Percent Volume Receiving \geq Rx Dose(D1)	ICRU Ref Dose (Gy)	2% Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)	Coverage Score
PTV1	310	100 % \geq 55.8 Gy	73.0	74.4	57	73	1
PTV2	242.4	100 % \geq 70.2 Gy		74.4	68	73.4	1
PTV	---	--- % \geq --- Gy	*	---	---	---	---
CTV	113	99.3 % \geq 70.2 Gy	*	74.4	65.4	74	1
GTV	89	100 % \geq 70.2 Gy		74.2	72	74	1

Target Volume Coverage Score: 1: $V_{RxD} \geq 98\%$, 2: $95\% \leq V_{RxD} < 98\%$, 3: $V_{RxD} < 95\%$ or $V_{RxDCTV \text{ or } GTV} < 100\%$.

B. DOSE HETEROGENEITY(DH) And CONFORMITY

	Conformity Index*	Dose Heterogeneity	Dose Heterogeneity Score
PTV(2)	---	1.02 ✓	1

Dose Heterogeneity (2% Max Dose/Rx dose): 1: $DH \leq 1.07$, 2: $1.07 < DH \leq 1.10$, 3: $DH > 1.10$

C. NORMAL STRUCTURE ANALYSIS (See appendix II for standard structure names)

Normal Tissue	Volume (cc)	% Vol \geq Ref Dose (D1)	Ref Dose (D1) (Gy)	Max Dose (Gy)	Mean Dose (Gy)
Bladder	112	50	65.0	74.4	61.1
Left Femur	192	0	52.0	41	34.4
Right Femur	187	0	52.0	42	33.0
Rectum	87	30	60.0	74.3	49
Penile Bulb	9.3	55.2	70.0	73	68
Unspecified Tissue	23710	0.9	58.9	74.4	8

Reviewed by: lquarles Date: 12-1-04

After completing this form please FAX to the ITC: (314)747-5423.



Radiation Therapy
Oncology Group

Plan Summary

Image-guided Therapy Center

Protocol: 0126 Case: 0009 (Plan ID: totalhetero) Plan Date: Mon Nov 18 11:06:31 2005
Plan Description: composite plan

Calculation Volume Size: Width(x) 42.3(cm) x Depth(y) 28.8(cm) x Height(z) 26.1(cm) [142 x 145 x 88]
Center: X = 0.8, Y = -2.1, Z = 3.1 SITK: Prostate MD: cross

Beam # (Field):	1	(_____)	2	(_____)	3	(_____)	4	(_____)
Description:		>Ant (B1)		>Post (B2)		>Right (B3)		>Left (B4)
Machine ID:		15MVXRAYS		15MVXRAYS		15MVXRAYS		15MVXRAYS
Setup Distance:		100.0 cm SAD		100.0 cm SAD		100.0 cm SAD		100.0 cm SAD
Isocenter Depth:	ODI(_____)	11.4 cm	ODI(_____)	12.5 cm	ODI(_____)	20.4 cm	ODI(_____)	20.1 cm
Isocenter Coord:		0.8, -3.9, 2.7 cm		0.8, -3.9, 2.7 cm		0.8, -3.9, 2.7 cm		0.8, -3.9, 2.7 cm
Entry Point:		0.8, -3.9, 14.1 cm		0.8, -3.9, -9.8 cm		-19.5, -3.9, 2.7 cm		20.9, -3.9, 2.7 cm
Coll. Width (cone):	X1:	5.0 cm	X1:	5.2 cm	X1:	4.8 cm	X1:	4.0 cm
	X2:	5.0 cm	X2:	5.1 cm		4.1 cm	X2:	5.0 cm
Coll. Length (cone):	Y1:	6.3 cm		12.5 cm	X2:	12.5 cm	Y1:	6.3 cm
	Y2:	6.1 cm					Y2:	6.2 cm
Collimator Angle:		180 degrees		180 degrees		180 degrees		180 degrees
Couch Angle:		180 degrees		180 degrees		180 degrees		180 degrees
Head/Foot Orient:		Head to Gantry		Head to Gantry		Head to Gantry		Head to Gantry
Gantry Angle:		180 degrees		360 degrees		270 degrees		90 degrees
Rotation Arc:		x x x		x x x		x x x		x x x
Comp Filter Used:		NO COMPENSATOR						
Bolus Used:		NO BOLUS USED		NO BOLUS USED		NO BOLUS USED		NO BOLUS USED
Wedge (Normal):								
Wedge Orientation:								
ICRU Ref Pt (cGy):		1739 TD		1739 TD		1159 TD		1162 TD
Film Link/Aligned:								

Page# 1 of 2 [Max Point Dose = 7472]
Plan Info (Total ICRU Dose: 7296 [Sampled Dose Value: 7300])





Radiation Therapy
Oncology Group

Remote Review Tool - Case: 0126c0009

Page 1 of 1


Image-guided Therapy Center

Remote Review Tool

PROTOCOL: 0126

CASE: 0009

STRUCTURE: PTV1



Plan ID	% Vol >= D1 (55.8 Gy)	% Vol >= Dref (55.8 Gy)	Max Dose (Gy)	Min Dose (Gy)	Mean Dose (Gy)
totalhetero	100.0	100.0	74.7	56.9	72.7

Calculated: Fri Apr 16 14:08:26 2004 (/web/RTOP/patient/0126c0009/olddump.dat)

Printed Fri Jan 14 09:48:51 CST 2005

[Close window](#)

<https://cancer.wustl.edu:8443/Review/RRT/printdvh.cgi?PTV1>

1/14/2005



Radiation Therapy
Oncology Group

IMAGE-GUIDED THERAPY CENTER [ITC]

Protocol H0022 Dose-Volume Analysis QA Review for:

Patient Name: 0013 Physician: _____

Institution: _____ QA Center ID: _____

A. TARGET VOLUME ANALYSIS

Targ. Vol.	Volume (cc)	% Vol ≥ Rx Dose		% Vol > 110% Rx Dose		% Vol ≥ X% of Rx Dose (Gy)		% Vol ≥ Y% of Rx Dose		Max. Dose Gy	Min Dose Gy	Mean Dose Gy	Score
PTV66	42	100	66.0	7.3	72.6	100	61.4			75	62.2	70.3	1
PTV54	492	95.3	54.0	38	39.4	100	47.0	0	72.6	74.4	29.4	59	1

Scoring is: 1 – No Variation; 2 – Minor Variation; 3 – Major Variation [The volume of PTV66 MUST be subtracted out of the PTV54 DVH]

B. DOSIMETRIC SCORE

Score	PTV66 Dose Coverage			PTV54 Dose Coverage		
1	95% of PTV66 ≥ 66 Gy	99% of PTV66 ≥ 60.0 Gy	80% of PTV66 ≤ 72.6 Gy	95% of PTV54 ≥ 54 Gy	99% of PTV54 ≥ 50.2 Gy	80% of PTV54 ≤ 59.4 Gy
2	90% of PTV66 ≥ 66 Gy	99% of PTV66 ≥ 60.0 Gy	75% of PTV66 ≤ 72.6 Gy	90% of PTV54 ≥ 54 Gy	99% of PTV54 ≥ 47.0 Gy	80% of PTV54 ≤ 72.6 Gy
3	<90% of PTV66 ≥ 66 Gy	<99% of PTV66 ≥ 60.0 Gy	<75% of PTV66 ≤ 72.6 Gy	<90% of PTV54 ≥ 54 Gy	<99% of PTV54 ≥ 47.0 Gy	<80% of PTV54 ≤ 72.6 Gy

C. NORMAL STRUCTURE ANALYSIS

Target Volume	Volume (cc)	% Vol. ≥ Reference Dose	Max. Dose (Gy)	Mean Dose (Gy)	Constraint(s) Met	Score	
Parotid Lt	40.1	26.4	30.0 Gy	58	22.4	<input type="checkbox"/> Y <input type="checkbox"/> N	1
Parotid Rt	37.3	93	30.0 Gy	71.2	50.2	<input type="checkbox"/> Y <input type="checkbox"/> N	
Parotid Total	77.3	72	30.0 Gy	71.2	36	<input type="checkbox"/> Y <input type="checkbox"/> N	
Mandible	62.3	1.1	70.0 Gy	73	35.1	<input type="checkbox"/> Y <input type="checkbox"/> N	
Larynx	3	0	50.0 Gy	43.2	23	<input type="checkbox"/> Y <input type="checkbox"/> N	
Brain Stem	29	0	54.0 Gy	50	7.1	<input type="checkbox"/> Y <input type="checkbox"/> N	
Spinal Cord	13.1	0	45.0 Gy	40	17	<input type="checkbox"/> Y <input type="checkbox"/> N	
Non-Target Tissue	11774	1	58.9 Gy	73	12	<input type="checkbox"/> Y <input type="checkbox"/> N	
Composite Score						1	

Score	Parotid Sparing				
1	Mean dose to either gland < 26 Gy	or	50% of either gland ≤ 30 Gy	or	20 cc of combined glands < 20 Gy
2	≤ 60% of either gland ≤ 30 Gy				
3	60% of either gland > 30 Gy				

Composite score is maximum of coverage and parotid sparing scores.

Reviewed by: Iquarles

Date of Review: 10-29-04

Rev. 20Mar02





Radiation Therapy
Oncology Group

RTOG Headquarters Report

RTOG Protocols supported by the ATC (as of April 1, 2005)

- 12 Studies (7 Active / 5 closed, data analysis continues)
 - RTOG 94-06: Phase I/II Dose Escalation Study Using 3D Conformal Radiation Therapy for Adenocarcinoma of the **Prostate** (closed, data analysis continues)
 - 54 institutions credentialed; 1084 patients registered to study
 - RTOG 93-11: Phase I/II Dose Escalation Study Using 3D Conformal Radiation Therapy in Patients with **Inoperable NSCLC** (closed, data analysis continues)
 - 27 institutions credentialed; 180 patients registered to study
 - RTOG 98-03: Phase I/II Radiation Dose Escalation Study Applying Conformal Radiation Therapy in Supratentorial **Glioblastoma Multiforme** (closed, data analysis continues)
 - 46 institutions credentialed; 210 patients registered to study



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

RTOG Protocols supported by the ATC (as of April 1, 2005) (cont.)

- RTOG 0319: Phase I/II Study to Evaluate 3DCRT Irradiation Confined to Region of the Lumpectomy Cavity for Stage I/IIA **Breast Carcinoma** (study closed, data analysis continues)
 - 31 institutions credentialed; 58 patients registered to study; 54 cases reviewed via RRT.
- RTOG 0022: Phase I/II Study of Conformal And Intensity Modulated Irradiation for **Oropharyngeal Cancer** (study closed, data analysis continues)
 - 31 institutions credentialed; 69 patients registered to study



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

RTOG Protocols supported by the ATC (as of April 1, 2005) (cont.)

- RTOG 0117: Phase I/II Dose Intensification Study using 3DCRT and Concurrent Chemotherapy for Patients with Inoperable **NSCLC**
 - 41 institutions credentialed; 23 patients registered to study; Target Accrual – 73
- RTOG 0126: Phase III Randomize Study of High Dose 3DCRT/IMRT versus Standard Dose 3DCRT/IMRT in Patients treated for Localized **Prostate Cancer** (9/18/03 IMRT allowed)
 - 117 institutions credentialed; 523 patients registered to study; 125 cases reviewed via RRT; Target Accrual – 1520
- RTOG 0225: Phase I/II Study of Conformal And Intensity Modulated Irradiation for **Nasopharyngeal Cancer**
 - 32 institutions credentialed; 45 patients registered to study; Target Accrual – 64



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

RTOG Protocols supported by the ATC (as of April 1, 2005) (cont.)

- RTOG 0232: Phase III Study Combined XRT & Brachytherapy vs. Brachytherapy alone for **Prostate Cancer**.
 - 52 institutions credentialed; 105 patients registered to study; Target Accrual – 1520
- RTOG 0236: Phase II Study of Extracranial Stereotactic Radioablation in Treatment of Patients with Medically Inoperable Stage **NSCLC**
 - 4 institutions credentialed; 7 patients registered to study; Target Accrual – 52
- RTOG 0321: Phase I/II Prostate: HDR Brachytherapy and XRT for **Prostate Cancer**.
 - 4 institutions credentialed; 7 patients registered to study; Target Accrual – 110
- RTOG 0413/NSABP B-39: Phase III Study of Whole Breast RT versus Partial Breast Irradiation for **Breast Cancer**.
 - 5 institutions credentialed; Target Accrual = 3000.



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)

Pending RTOG Protocols -- ATC Resources Requested: N=8

- RTOG 0515(0238): A Phase I/II Study of GTV Definition with PET Fusion for NSCLC.
- RTOG 0438(0245): Phase I Study of Stereotactic RT for Hepatic Cancer (Mets or Primary CA).
- RTOG 0415: Phase III Randomized Study of Hypofractionated 3DCRT/IMRT vs. Standard 3DCRT/IMRT for Prostate Cancer.
- RTOG 0418: Phase II Study of IMRT + chemo for selected GYN (cervix or endometrial) cancer.
- RTOG 0529: Phase II Study of IMRT + chemo for Anal Cancer.



Radiation Therapy
Oncology Group

RTOG Headquarters Report (cont.)


Pending RTOG Protocols (ATC Resources Requested: (cont.))

- RTOG 0421: Phase III Head & Neck: Re-irradiation + chemo versus Chemo alone for Recurrent Head and Neck Cancer (*?certification only).
- RTOG 0436: Phase III Esophagus: Chemoradiation with or without Cetuximab. (*?certification only)
- RTOG 0522: Phase III Advanced Unresectable Head & Neck Cancer: Chemoradiation with or without Cetuximab. (*?certification only).



Radiation Therapy
Oncology Group

RTOG 0232 Prostate – Brachytherapy Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0232



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Radiation Oncologist, M.D.
Institution – CTSU
Address
City, State, Zip Code

Dear Dr.:

The Credentialing process by the Radiological Physics Center (RPC) for prostate brachytherapy and Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG-0232 – A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma has been successfully met.

You are now approved to enter patients onto RTOG Prostate Implant Protocol 0232. A change in Radiation Oncologist, Physicist, treatment planning system, nuclide or seed model will require recredentialing by the RPC and/or ITC.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
Dosimetrist
RTOG Randomization
ITC
RPC
CTSU

Supported by the Division of Cancer Treatment and Diagnosis, National Cancer Institute



Radiation Therapy
Oncology Group

Credentialed Institutions

RTOG – 0232 (52 Institutions Credentialed)

RTOG Inst. #	RTF #	Name	Source	Approved	Physician	Physicist	TX Planning Sys	Dry Run Sub. ITC	Dry Run Approval
		RTOG Protocol P-0232							
	2650	Vanderbilt							
			i-plant	05/05/03	Ming Teng	Charles Coffey, Bob Aus	Rosses		
			iogold,prostaseed, pd200,pdgold, best pd						
7718	1192	Univ. of TX, San Antonio (Can. Ther. Res. Ctr)		05/16/03	Bradley Prestidge	William Bice	Home Grown and Variseed		
5922	1775	Mary Bird Perkins		07/18/03	Sheldon A. Johnson	Angela Stam	Varian Variseed		
2102		Washington University Medical Center		07/18/03	Jeff Michalski		Varian Variseed		
3401	2215	Roswell Park Cancer Institute		08/08/03	Michael Kuettel	Matthew Podgorsak	Varian Variseed		
	2687	Wake Forest University Baptist Med. Ctr.		09/04/03	W. Robert Lee	Allan deGuzman	Varian Variseed		
1518	1011	Akron City Hospital		09/29/03	Michael Seider	Stanley Phillips	Varian Variseed		
2501	1675	LDS Hospital		10/27/03	R. J. Lee, M.D.	David Matthes			
0137	2700	Washoe Medical Center		11/04/03	Lawrence Dardick, M.D.	Richard Erickson, M.S.	Varian Variseed		
5803	2805	South Suburban Oncology Center		11/14/03	H. Joseph Barthoid, M.D.	Sheri Weintraub, M.S.	Varian Variseed		
7501		Cross Cancer Institute		11/14/03	John Pedersen, M.D.	Ron Sloboda, Ph.D.	Varian Variseed		
					Joseph Cardinale, M.D.				
0152		Hospital of St. Raphael		11/18/03	Francis Cardinale, M.D.	Per Halvorsen, M.S.	Varian Variseed		
CTSU		Memorial Medical Center		12/05/03	Thomas Shanahan, M.D.	Randy Maxey, M.S.	Varian Variseed		
					Juanita Crook, M.D.				
2215		Princess Margaret Hospital		12/31/03	Michael McLean, M.D.	Ivan Yeung	Varian Variseed		
					Thomas Pisansky, M.D.	Robert W. Kline, Ph.D.			
					Brian J. Davis, M.D.	Luke McLemore, M.S.			
0184		Mayo Clinic		01/14/04	Derek L. Shickell, M.D.	C. Robert Blackwell,	Varian Variseed		
					Seth Rosenthal, MD				
					David Instadt, MD				
6201		Radiological Associates of Sacramento		01/21/04	Mark Leibenhaut, MD	Miriam Lambert, Ph.D.	Varian Variseed		
							Amersham model 6711		
5301	2120	Queen's Medical Center in Honolulu		02/02/04	John L. Lederer, M.D.	Edwin Price, Ph.D.			
						Jadwiga B. Wojcicka, Ph.D.			
0629		York Cancer Center, Wellspan		02/11/04	Amit Shah, M.D.		Varian Variseed		
9610		McKay Dee Hospital Center		02/12/04	Gary Whipple, M.D.	Mark Amfield, Ph.D.	Varian Variseed		
					Pradip Amin, M.D.				
5702		University of Maryland Medical Systems		02/16/04	William Regine, M.D.	Mehrdad Sarfaraz, Ph.D.	Variseed		
3701	1021	Allegheny General Hospital		03/15/04	Russell Fuhrer, M.D.	Mark Johnson, M.S.	Varian Variseed		
5901	1744	Univ of TX-MD Anderson Cancer Center		03/31/04	Deborah Kuban, M.D.	Ann Lawyer, M.S.	Varian Variseed		
						Ram Virudachalam, Ph.D.			
2426	1914	Mount Diablo Medical Center		03/31/04	Daniel Chinn, M.D.		Varian Variseed		
0180	1918	Mt. Sinai Comprehensive Can. Ctr.		04/14/04	Leonard Toonkel, M.D.	Francis Chang, Ph.D.	Varian Variseed		
7015	2704	Waukesha Memorial Hospital		05/07/04	Wingate Clapper, M.D.	Eric Hendee, M.S.	Varian Variseed		
5101	1016	Albert Einstein Medical Center		05/07/04	Kenneth Zeltzer, M.D.	Feng Zhou, M.S.	Varian Variseed		
0601	1451	Frankford Hospital		05/07/04	Eric Gressen, M.D.	Jinyu Xue, Ph.D.	Varian Variseed		
					Adam Dicker, M.D.				
0601	1640	Thomas Jefferson University Hospital		05/07/04	Richard Valicenti, M.D.	Hayeon Kim, M.S.	Varian Variseed		
					Michael Hagan, M.D.				
9520	1788	McGuire Veterans Admin. Med. Ctr.		05/10/04	Anthony Addesa, M.D.	Nirmal Sakthi	Varian Variseed		
0488	1512	H. Lee Moffitt Cancer Center		05/28/04	Randy Heysek, M.D.	Amarjit S. Saini, M.S.	Varian Variseed		
2217	1066	Baptist Medical Center		05/28/04	Douglas Johnson, M.D.	Norman Brown, M.S.	Varian Variseed		
8201	2619	University of Utah Hospital & Clinics		05/28/04	Dennis C. Shrieve, M.D.	Jim Rankin	Varian Variseed		
5710	2344	St. Agnes Cancer Center		06/01/04	Richard Hudes, M.D.	Timothy Holmes, Ph.D.	Varian Variseed		
1524	1104	Beth Israel Medical Center		06/29/04	Daniel Shasha, M.D.	Lin Wang, M.S.	Varian Variseed		
2417	1166	California Cancer Center		07/22/04	Douglas Wong, M.D.	Georg Weidlich, Ph.D.	Varian Variseed		
0526	2597	University of Kentucky		07/23/04	William St Clair, M.D.	All Melgooli, Ph.D.	Varian Variseed		
7001	1460	Medical College of Wisconsin		08/06/04	Colleen Lawton, M.D.	Paul Jursinic, Ph.D.	Varian Variseed		
7002	1294	Community Memorial Hospital		08/11/04	Colleen Lawton, M.D.	Paul Jursinic, Ph.D.	Varian Variseed		
CTSU	1203	Capital Health System - Mercer Campus		08/23/04	Daniel K. Fram, M.D.	Gregory Desobry, Ph.D.	Varian Variseed		



Radiation Therapy
Oncology Group

Approved Institutions

RTOG – 0022 & 0225 (Pharynx CA)

31 Sites Credentialed; 67 Sites in process

Institution	NCI #	RTOG Inst.#	ITC Dry Run Approval	Digital Phantom Data Submission to ITC	ITC Acceptable	RTF #	Phantom Irradiation	RPC Phantom Approval	RPC Acceptable	Status	Repeats	RPC Acceptable	Overall Approval
Akron City Hospital	OH055	1518	01/07/2005	01/07/2005	Yes	1011	03/04/2004	03/29/2004	Yes	Active			Yes
Albert Einstein Medical Center	PA094	5101				1016	06/01/2004	08/16/2004	Yes	Active			
Albuquerque Regional Medical Center													
Northeast Heights Cancer Center													
Radiation Oncology Associates of Albuquerque	NM001	0503	11/10/2004	11/01/2004	Yes	2406	04/12/2004	05/12/2004	Yes	Active	N/A	N/A	Yes
Alta Bates Comprehensive Cancer Center	CA164	9600				1025	06/18/2004	08/04/2004	Yes	Active			
Baptist Medical Center						1066	06/18/2004	08/04/2004	Yes	Active			
Baptist Hospital of Miami	FL078	8903				1065	11/19/2004	01/07/2005	Yes	Active			
Baylor College of Medicine		7011				1088	05/17/2004	05/17/2004	Yes	Resign-4/1/95			
Beith Israel Deaconess Medical Center	MA038	9641				1103	08/26/2004	10/20/2004	Yes	Active			
Brigham & Women's Hospital/Dana Farber Cancer Institute	MA037	9626				1722	01/03/2005	02/18/2005	Yes	Active			
California Cancer Center						1166	08/18/2002	08/20/2003	No	Active			
Cancer Center at Saint Agnes	CA112	2431				1182	07/27/2004	08/23/2004	Yes	Active			
Cancer Therapy and Research Center	TX059	7718				1193	06/04/2004	08/31/2004	Yes	Active			
Central Wisconsin Cancer Program (St. Agnes, Wisconsin)	WI060	7013				1231	02/04/2003		No	Resign-12/31/96			
Charleston Radiation Therapy Consultants						1238	05/13/2004	06/16/2004	Yes	Active			
Christiana Care Health System	DE002	8918				1256	06/28/2004	08/13/2004	Yes	Active			
Christus St. Joseph Hospital						2404	01/13/2005	02/11/2005	Yes	Active			
Cleveland Clinic Foundation	OH027	6001				1269	08/10/2004	09/22/2004	Yes	Active			
Community Medical Center	NJ070	2211	07/29/2004	07/29/2004	Yes	1293	01/16/2004	02/13/2004	Yes	Active	N/A	N/A	Yes
Gross Cancer Institute	11104	7501	12/21/2001	12/21/2001	Yes	1313	07/29/2001	1st 10	Yes	Active	N/A	N/A	Yes
Dartmouth-Hitchcock Medical Center	NH012	8902	01/07/2005	01/07/2005	Yes	1325	08/31/2004	10/20/2004	Yes	Active			Yes
Emory Clinic	GA005	1523				1401	06/04/2004	02/12/2004	Yes	Active			
Fairview University Medical Center	MN022	1312				2003	04/28/2004	05/27/2004	Yes	Active			
Falk Cancer Center	NY170	0627				1040	08/31/2004	10/20/2004	Yes	Resign - 4/15/97			
Flower Memorial Hospital		7690				1440	11/02/2002	12/03/2003	No	Active			
Fox Chase Cancer Center	PA066	2212				1449	12/02/2002	11/20/2003	No	Resign-2/21/00	Repeat - 9/4/03	Yes	
Georgetown University Medical Center	DC005	5487				1471	03/28/2003	06/19/2003	No	Active			
Geisinger Medical Center	PA052	0181				1463	08/31/2004	09/24/2004	Yes	Active			
Good Samaritan, Portland OR		2133	02/20/2003	05/07/2003	Yes	1483	04/30/2003	06/06/2003	Yes	Resign-10/1/95	Repeat - 7/25/03	Yes	Yes
H. Lee Moffitt Cancer Center	FL079	0488	11/18/2003	11/18/2003	Yes	1512	01/16/2004	03/02/2004	Yes	Active	N/A	N/A	Yes
Holmes Regional Medical Center	FL021	2236				1557	07/17/2002	09/18/2003	No	Resign-1/21/03	Repeat - 7/7/03	Yes	
Hughes Cancer Center - Pocono Medical Center						2084	11/19/2006	01/04/2006	Yes	Not a Member			
Intercommunity Cancer Center, Cincinnati, OH						1602	09/19/2003	09/19/2003	Yes	Resign-4/15/97	Repeat - 2/18/05	Yes	
Iowa Methodist Medical Center	IA004	0200				1626	04/24/2003	06/16/2003	No	Active	N/A	N/A	Yes
John's Hopkins	MD017	5701	04/03/2003	03/31/2003	Yes	1662	01/20/2003	06/06/2003	Yes	Active			
Johnson City Medical Center	TN011	5804				1653	02/27/2004	03/18/2004	Yes	Active			
Kaiser Permanente-Radiation Oncology Center						2974	01/13/2005	02/09/2005	Yes	Active			
Kansas City Cancer Centers-Southwest (CCOP)	MO058	0126	01/13/2004	01/13/2004	Yes	1654	02/13/2004	03/17/2004	Yes	Active	N/A	N/A	Yes
Kansas City Hospital (North Kansas City Hospital)	MO058	0126	07/29/2004	07/29/2004	Yes	1978	07/28/2004	08/31/2004	Yes	Active	N/A	N/A	Yes
Lankenau Hospital	PA163	0258	05/26/2004	05/26/2004	Yes	1148			Yes	Active			
LDS Hospital	UT004	2501				1675	12/12/2003	01/15/2004	Yes	Active			
Lutheran General Hospital	IL010	0722				1732	12/08/2004	12/08/2004	Yes	Active			
M.D. Anderson Cancer Center	TX035	5901	11/14/2001	11/14/2001	Yes	1744	04/14/2001	1st 10	Yes	Active	N/A	N/A	Yes
MD Anderson Brazosport						1743	07/07/2004	08/23/2004	Yes	Active			
Mary Bird Perkins Cancer Center	LA002	8902	06/28/2004	06/28/2004	Yes	1775	09/23/2004	08/31/2004	Yes	Active	N/A	N/A	Yes
Massachusetts General Hospital	MA034	5801				1783	05/08/2003	1st 10	Yes	Active			
Mayo Clinic, Rochester, MN	MN026	0184	10/18/2004	10/18/2004	Yes	1785	05/20/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
McGill University	11152	1201	03/25/2004	03/25/2004	Yes	1903	12/08/2003	02/04/2004	Yes	Active	N/A	N/A	Yes
McKay-Dee Hospital Center	UT007	9610	11/03/2004	11/03/2004	Yes	2807	03/16/2004	04/13/2004	Yes	Active	N/A	N/A	Yes
McLaren Regional Cancer Center	MI060	2209				1790	06/04/2004	06/04/2004	Yes	Active			
Medical College of Wisconsin	WI013	7001	02/20/2002	02/20/2002	Yes	1460	03/09/2001	1st 10	Yes	Active	N/A	N/A	Yes
Memorial Health University Medical Center						1810			No	Active			
Memorial Sloan-Kettering Cancer Center	NY016	2301	01/06/2004	01/06/2004	Yes	1823	10/31/2003	12/04/2003	Yes	Active	N/A	N/A	Yes
Mormouth Medical Center	NJ068	2242				1897	10/04/2004	12/01/2004	Yes	Active			
Naval Medical Center Portsmouth	VA024	2245				1941	06/16/2003	07/18/2003	Yes	Active			
Northwest Community Hospital	IL001	7705					08/20/2003	12/02/2003	Yes	Active			
Northwestern Memorial Hospital	IL036	2116				2163		07/12/2004	Yes	Active			



Radiation Therapy
Oncology Group

RTOG/ATC Challenges

- Faster Protocol Development process.
- Incentivization for RTOG members to become certified.
- Increased accrual to selected studies, e.g. 0232.
- Enormous amount of data has been collected – needs to be analyzed!



Radiation Therapy
Oncology Group

ATC Meeting Schedule

- Monthly teleconferences are held on the first Wednesday of each month to keep all ATC participants up to date on ongoing activities. Next call on May 4, 2005 at 2:00 CST.
- Bi-weekly teleconferences are held on Friday for RTOG/ITC/RPC Specific issues.
- ATC meeting at the RTOG Semi-Annual Meeting in Philadelphia, PA, Loews Philadelphia Hotel, June 23, 2005 at 8:00am – 5:00pm.



Radiation Therapy
Oncology Group

R. T. Quality Assurance Staff



**Back Row L/R: Lorraine Quarles; Denise Manfredi; Tammy McGlade;
Betty Martin; Joanne Hunter**
Front Row L/R: Darlene Herd; Julie McIlvaine




Radiation Therapy
Oncology Group



Radiation Therapy
Oncology Group

RTOG 0225 IMRT H&N – Nasopharyngeal Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0022 & 0225



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

The IMRT Head and Neck Phantom irradiation component of the credentialing process reviewed by the Radiological Physics Center (RPC) and the testing for the dry run case through the Image-Guided Therapy Center (ITC) for RTOG 0022 – Phase I/II Study of Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer and RTOG 0225 – Phase II Study of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy for Nasopharyngeal Cancer has been successfully met.

You are now approved to enter patients onto RTOG Protocol 0022 and RTOG 0225.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance



Radiation Therapy
Oncology Group

Approved Institutions

RTOG – 0022 & 0225 (cont.)

31 Institutions Credentialed

67 Institutions in process

Institution	NCI #	RTOG Inst.#	ITC Dry Run Approval	Digital Phantom Data Submission to ITC	ITC Acceptable	RTF #	Phantom Irradiation	RPC Phantom Approval	RPC Acceptable	Status	Repeats	RPC Acceptable	Overall Approval
Palmetto Health Richland Hospital	11030	2215				1626		2/11/2005	Yes				
Princess Margaret Hospital	H004	5301				2100	03/12/2004	04/06/2004	Yes	Active			
Queen's Medical Center, Honolulu, Hawaii	H004	5301				2120	02/25/2003	06/23/2003	Yes	Active			
Radiation Oncology Centers of Las Vegas	NV012	0137	10/13/2004	10/13/2004	Yes	2138	02/24/2004	03/17/2004	Yes	Active	N/A	N/A	Yes
Radiological Associates Sacramento (Butter)	CA269	6201	05/22/2003	01/10/2003	Yes	2503	10/16/2003	12/05/2003	Yes	Active	N/A	N/A	Yes
Rapid City Regional Hospital	SD006	0206				2163	06/06/2004	07/12/2004	Yes	Active			
Regional Radiology Oncology Center, Rome, GA	GA059	5490				1621	07/01/2004	08/23/2004	Yes	Active			
Robert Wood Johnson University Hospital	NJ053	0633				2913	03/08/2004	04/07/2004	Yes	Active			
Roper Hospital		4512				2212	06/04/2004	06/04/2004	Yes	Active			
Rosewell Park Cancer Institute	NY158	3401	04/13/2004	04/13/2004	Yes	2215	11/11/2003	11/11/2003	Yes	Active	N/A	N/A	Yes
Saskatoon Cancer Center	11120	7512	12/10/2001	12/10/2001	Yes	2260	11/09/2001	1st 10	Yes	Active	N/A	N/A	Yes
Sentara Norfolk General Hospital	VA052	6485				2271	11/01/2003	01/13/2004	Yes	Active			
St Luke's Bethlehem, PA	PA054	1324				2433	06/18/2003	07/18/2003	Yes	Active			
St. Vincent Hospital		7010	03/10/2005	03/10/2004	Yes								
Swedish Cancer Institute						2560	11/24/2003	11/24/2003	Yes				
Thomas Jefferson University	PA121	0601	11/14/2001	11/14/2001	Yes	1640	09/28/2000	1st 10	Yes	Active	N/A	N/A	Yes
Thompson Cancer Survival Center	TN038	2111				2530	07/20/2004	08/23/2004	Yes	Resign - 9/5/97			
Tom Baker Cancer Centre	11134	8901	06/23/2003	06/23/2003	Yes	2535	02/24/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
University Hospital of Cincinnati	OH070	2113				2569	01/22/2004	03/03/2004	Yes	Active			
University of Alabama at Birmingham	AL002	2110	06/30/2003	06/30/2003	Yes	2582	05/28/2003	06/30/2003	Yes	Active	N/A	N/A	Yes
University of California, Davis, Sacramento, CA 95817	CA189	3423	07/29/2004	07/29/2004	Yes	2584	10/27/2003	12/09/2003	Yes	Active	N/A	N/A	Yes
University of California San Francisco	CA136	2401	04/10/2002	04/10/2002	Yes	2584	02/27/2002	1st 10	Yes	Active	N/A	N/A	Yes
University of Florida, Gainesville	FL015	3228				2592	02/12/2002	1st 10	Yes	Active			
University of Illinois Medical Center	IL040	9556				2594	08/31/2004	10/21/2004	Yes	Resign - 1/17/02			
University of Maryland	MD015	5702				2599		01/07/2005	Yes	Active			
University of Michigan Medical Center	MI014	2235	06/16/2003	06/16/2003	Yes	2602	01/28/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
University of North Carolina Hospitals	NC007	6501				2608	12/15/2004	11/08/2004	Yes	Resign - 10/1/04			
University of Pennsylvania	PA029	2201				2610	02/19/2004	03/17/2004	Yes	Resign-12/2/03			
University of Pittsburgh at Shadyside	PA015	6901				2277	12/13/2004	01/06/2005	Yes	Unspecified			
University of Rochester	NY167	0501				2613	02/20/2004	04/08/2004	Yes	Active			
University of Texas Medical Branch, Galveston	TX045	6401	04/10/2002	04/10/2002	Yes	2618	02/11/2002	1st 10	Yes	Active	N/A	N/A	Yes
University of Utah	UT003	8201				2619	05/17/2004	05/17/2004	Yes	Active			
University of Wisconsin	WI020	0801	06/23/2003	06/23/2003	Yes	2622	05/14/2003	06/23/2003	Yes	Active	N/A	N/A	Yes
UT Southwestern Medical Center	TX011	5915				2629	09/10/2004	09/24/2004	Yes	Active			
Virginia Mason Medical Center	WA054	0131	03/09/2005	03/09/2005	Yes	2681	04/30/2004	05/26/2004	No	Active	Repeat - 7/24/03	Yes	Yes
Wake Forest University School of Medicine	NC002	5483				2687	11/14/2003	02/10/2004	Yes	Active			
Washington University	MO011	2101	03/02/2004	03/02/2004	Yes	1076	08/08/2001	1st 10	Yes	Active	N/A	N/A	Yes
Waukesha Memorial Hospital	WI051	7015				2704	06/24/2002	06/23/2003	Yes	Active			
Western Pennsylvania Hospital	PA018	7008				2729	05/17/2004	05/17/2004	Yes	Active			
Wilkes-Barre General Hospital	PA060	1323				2741	10/22/2005	05/06/2004	No	Active	Repeat - 7/13/03	Yes	
William Beaumont Hospital, Royal Oak, MI	MI005	7200	02/27/2003	05/12/2003	Yes	2744	05/07/2003	01/13/2004	Yes	Active	N/A	N/A	Yes
York Cancer Center	PA047	0629				1034	04/04/2004	06/06/2004	Yes	Active			



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

Since your institution has been credentialed for the IMRT Head and Neck protocols (RTOG 0022 & RTOG 0225) you will be automatically credentialed to participate in the Prostate protocol using IMRT (RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer). You will not be required to do additional credentialing for the use of IMRT on RTOG 0126.

You are now approved to enter patients onto RTOG Protocol 0126.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr.:

The Credentialing process by the Radiological Physics Center (RPC) for irradiating the Head and Neck Phantom using IMRT has been successfully met. The Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer has also been successfully met.

You are now approved to enter patients onto RTOG Protocol 0126.

You are not approved to enter patients onto Head and Neck Protocols using IMRT (RTOG 0022 and RTOG 0225). If in the future you wish to enter patients onto Head and Neck Protocols using IMRT, you will be required to complete the Dry Run test for the Head and Neck IMRT study.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1818 Market Street, Suite 1600
Philadelphia, PA 19103-3604
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Principal Investigator
Institution – RTOG # , NCI # , RTF #
Address
City, State, Zip

Dear Dr.:

The Credentialing process by the Radiological Physics Center (RPC) for irradiating the Pelvic Phantom using IMRT has been successfully met. The Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer has also been successfully met.

You are now approved to enter patients onto RTOG Protocol 0126.

You are not approved to enter patients onto Head and Neck Protocols using IMRT (RTOG 0022 and RTOG 0225). If in the future you wish to enter patients onto Head and Neck Protocols using IMRT, you will be required to irradiate the Head and Neck Phantom using IMRT and complete the Dry Run test for the Head and Neck IMRT study.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC

Supported by the Division of Cancer Treatment and Diagnosis, National Cancer Institute


American College of Radiology



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0126



Radiation Therapy Oncology Group

American College of Radiology
1101 Market Street, 14th Floor
Philadelphia, PA 19107
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Institution

Dear Dr. :

The Credentialing process including the Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0126 – Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer has been successfully met.

You are now approved to enter patients onto RTOG Protocol 0126 for 3D-CRT only.

Sincerely,

Elizabeth Martin
Director, R.T. Quality Assurance

cc: Physicist
Dosimetrist
Research Associate
RTOG Randomization
ITC
RPC



Radiation Therapy
Oncology Group

RTOG 0236

Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I/II Non-Small Cell Lung Cancer

SCHEMA

R
E
G
I
S
T
E
R

Stereotactic Body Radiation Therapy (SBRT),
20 Gy per fraction for 3 fractions over 1½-2
weeks, for a total of 60 Gy



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0236



Radiation Therapy Oncology Group

American College of Radiology
1818 Market Street, Suite 1600
Philadelphia, PA 19103-3604
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

, M.D.
Institution – RTOG # ; NCI # ; RTF #
Department of Radiation Oncology
Address
City, State, Zip

Dear Dr. :

Your institution has successfully completed the Lung Phantom Irradiation Dosimetry Test, Facility Questionnaire, Immobilization/Localization and Respiration Control Systems Test.

You can now enter patients on to RTOG Protocol 0236.

The Dry Run / Rapid Review will be reviewed on the actual case. The dosimetry will be reviewed and the study chair will determine if this and the drawn structures are protocol compliant and sufficient for the patient to go ahead with treatment. Since this test case (Dry Run / Rapid Review) is the first case entered from your institution, the scanning parameters, the structure outline, and the dosimetry will have to be according to protocol in order to pass the Dry Run / Rapid Review **PRIOR TO DELIVERING ANY PROTOCOL TREATMENT**. The plan will be reviewed centrally at the ITC, and suggestions regarding protocol compliance will be forwarded to your institution. The treatment plan for subsequent patients enrolled from your site will not be required to be centrally reviewed prior to treatment, but will be reviewed for protocol compliance at a later date.

However, the Immobilization/Localization and Respiration Control Systems Test must be repeated for the first 4 cases submitted from your institution and the results reviewed by James Galvin, D.Sc., Medical Physics Co-Chair. The data for the first patient entered must be reviewed and approved before you enter a second patient, and the results of the Immobilization/Localization and Respiration Control Systems Study for this patient must be approved prior to entering a third patient. At this point, any additional number of patients can be entered. You will have to send forward the results of the Immobilization/Localization and Respiration Control Systems Study for the third and fourth patients entered. Please refer to the attached information.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
James Galvin, D.Sc.
RTOG Randomization
ITC
RPC

Supported by the Division of Cancer Treatment and Diagnosis, National Cancer Institute


American College of Radiology



Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0236

RTOG Protocol 0236


Immobilization/Localization and Respiration Control Systems Study

This study must be performed on a single patient, and approval received from RTOG Headquarters, before you attempt to enter your first patient on RTOG Protocol 0236. A similar study must be performed for the first patient entered on this protocol, and approval must be received from Headquarters prior to entering a second patient. This same procedure must be followed before entering a third patient. A fourth patient can be entered at the same time as the third, as well as, additional patients can also be entered at this time. However, the results of the Immobilization/Localization and Respiration Control Systems Study for the third and fourth patients entered on this protocol must be sent forward for review as quickly as possible. This information will be analyzed, but no further communication will be sent from RTOG Headquarters except in those situations where problems are detected. If problems are found, you could be asked to stop entering patients until the issue is resolved. In situations where no problems are found, the Immobilization/Localization and Respiration Control Systems Study will be discontinued after you have sent the data forward for the fourth patient you have entered on this protocol.



Radiation Therapy
Oncology Group

RTOG 0321 Prostate – Brachytherapy Credentialing Process Notification





Radiation Therapy
Oncology Group

Institution Approval Letter for RTOG – 0321



Radiation Therapy Oncology Group

American College of Radiology
1818 Market Street, Suite 1600
Philadelphia, PA 19103-3604
(215) 574-3189
(800) 227-5463 Ext. 4189
(215) 928-0153 Fax

Date

Principal Investigator, M.D.
Institution – RTOG # ; NCI # ; RTF #
Department of Radiation Oncology
Address
City, State, Zip

Dear Dr. :

The Credentialing process by the Radiological Physics Center (RPC) for prostate brachytherapy and Electronic Data Submission to the Image-Guided Therapy Center (ITC) for RTOG 0321 – Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate has been successfully met.

You are now approved to enter patients onto RTOG Prostate Implant Protocol 0321. A change in Radiation Oncologist, Physicist, treatment planning system, HDR unit will require recredentialing by the RPC and/or ITC.

Sincerely,

Elizabeth A. Martin
Director, R.T. Quality Assurance

cc: Physicist
Research Associate
RTOG Randomization
ITC
RPC
CTSU



Radiation Therapy
Oncology Group

RTOG 0413

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

Randomization

GROUP 1*

Whole Breast Irradiation (WBI)

45-50 Gy in 25 (1.8-2.0 Gy)
fractions to whole breast,
followed by optional boost**
to ≥ 60 Gy

GROUP 2*

Partial Breast Irradiation (PBI)***

34 Gy in 3.4 Gy fractions using
multi-catheter interstitial brachytherapy

or

34 Gy in 3.4 Gy fractions using
MammoSite® balloon catheter

or

38.5 Gy in 3.85 Gy fractions using
3D conformal external beam radiation

For all PBI techniques: RT given to index
quadrant only, BID (with a fraction separation
of 6 hours), in 5-10 days.



Radiation Therapy
Oncology Group



Radiation Therapy
Oncology Group

Credentialed Institutions (cont.)

RTOG – 0232 (52 Institutions Credentialed)

RTOG Inst. #	RTF #	Name	Source	Approved	Physician	Physicist	TX Planning Sys	Dry Run Sub. ITC	Dry Run Approval
0181	1463	Gelsinger Medical Center		08/23/04	Omar Yumen, M.D.	Andrew Jones, Ph.D. Carla Setto Scofield, M.S.	Varian Variseed		
7016	2450	St. Mary's Regional Cancer Center		09/01/04	Doug Rock, M.D.	Larry Pallas, M.S.	Varian Variseed		
1022	2636	Virtua Memorial Hospital of Burlington County Gibbs Cancer Center		09/10/04	Lemuel Ariaratnam, M.D. Patricia Griffin, M.D.	Jose Garcia-Cobian, M.S. David Vassy, M.S.	Varian Variseed		
2132	2340	Spartanburg Regional Hospital		09/10/04	Drew Monitto, M.D.	Jim Turmel, M.S.	Varian Variseed		
CTSU	2229	Sacred Heart Medical Center		09/23/04	Gary VanHeuvelen, M.D.	Ray Luse, M.S.	Varian Variseed		
2501	1307	Cottonwood Hospital		10/07/04	R. Jeffrey Lee, M.D.	David Matthes	Varian Variseed		
	2265	Scottsdale Radiation Oncology							
2503	1042	Arrowhead Cancer Center		10/20/04	David Beyer, M.D.	Kevin Rogers, M.S.	Varian Variseed		
0503	2406	Radiation Oncology Associates of Albuquerque		10/28/04	Paul Anthony, M.D. Michael Haake, M.D.	David Lake, M.S.	Varian Variseed		
0528	1210	Carolinas Medical Center		11/17/04	Brad McCall, M.D.	Doug Frank, M.S.	CMS XIO		
8918	1256	Christiana Care Health Services		12/16/04	Vidon Donovani, M.D. Adam Raben, M.D.	Larry Simpson, Ph.D.	Varian Variseed		
2228	2168	Reading Hospital & Medical Center		12/22/04	Albert Yuen, M.D. Michael Haas, M.D.	Rene Smith, Ph.D.	Varian Variseed		
2401	2403	University of California San Francisco		12/22/04	Mack Roach, M.D.	Barby Pickett			
0501	2613	University of Rochester		12/28/04	Ralph Brasacchio, M.D.	Haisong Liu, Ph.D.	Rtek Piper		
1509	2313	South Nassau Communities Hospital		02/09/05	Louis Potters, M.D.	Joseph Presser, M.S.	Varian Variseed		